284 related articles for article (PubMed ID: 22178517)
21. Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.
Maciel M; Bauer D; Baudier RL; Bitoun J; Clements JD; Poole ST; Smith MA; Kaminski RW; Savarino SJ; Norton EB
Infect Immun; 2019 Nov; 87(11):. PubMed ID: 31427449
[TBL] [Abstract][Full Text] [Related]
22. DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.
García-Machorro J; López-González M; Barrios-Rojas O; Fernández-Pomares C; Sandoval-Montes C; Santos-Argumedo L; Villegas-Sepúlveda N; Gutiérrez-Castañeda B; Cedillo-Barrón L
Hum Vaccin Immunother; 2013 Nov; 9(11):2326-35. PubMed ID: 23880886
[TBL] [Abstract][Full Text] [Related]
23. Intranasal immunization with pneumococcal conjugate vaccines with LT-K63, a nontoxic mutant of heat-Labile enterotoxin, as adjuvant rapidly induces protective immunity against lethal pneumococcal infections in neonatal mice.
Jakobsen H; Bjarnarson S; Del Giudice G; Moreau M; Siegrist CA; Jonsdottir I
Infect Immun; 2002 Mar; 70(3):1443-52. PubMed ID: 11854231
[TBL] [Abstract][Full Text] [Related]
24. Enhanced immune response by amphotericin B following NS1 protein prime-oral recombinant Salmonella vaccine boost vaccination protects mice from dengue virus challenge.
Liu WT; Lin WT; Tsai CC; Chuang CC; Liao CL; Lin HC; Hung YW; Huang SS; Liang CC; Hsu HL; Wang HJ; Liu YT
Vaccine; 2006 Jul; 24(31-32):5852-61. PubMed ID: 16759760
[TBL] [Abstract][Full Text] [Related]
25. Transgenic tobacco expressed HPV16-L1 and LT-B combined immunization induces strong mucosal and systemic immune responses in mice.
Hongli L; Xukui L; Ting L; Wensheng L; Lusheng S; Jin Z
Hum Vaccin Immunother; 2013 Jan; 9(1):83-9. PubMed ID: 23108357
[TBL] [Abstract][Full Text] [Related]
26. Enterotoxigenic Escherichia coli Adhesin-Toxoid Multiepitope Fusion Antigen CFA/I/II/IV-3xSTa
Nandre R; Ruan X; Lu T; Duan Q; Sack D; Zhang W
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29263112
[TBL] [Abstract][Full Text] [Related]
27. Cyclic Dinucleotide-Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses.
Espinosa DA; Beatty PR; Reiner GL; Sivick KE; Hix Glickman L; Dubensky TW; Harris E
J Immunol; 2019 Feb; 202(4):1153-1162. PubMed ID: 30642979
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the LTK63 adjuvant effect on cellular immune responses to measles virus nucleoprotein.
Erume J; Partidos CD
Afr Health Sci; 2011 Jun; 11(2):151-7. PubMed ID: 21857843
[TBL] [Abstract][Full Text] [Related]
29. Protective immunity to Japanese encephalitis virus associated with anti-NS1 antibodies in a mouse model.
Li Y; Counor D; Lu P; Duong V; Yu Y; Deubel V
Virol J; 2012 Jul; 9():135. PubMed ID: 22828206
[TBL] [Abstract][Full Text] [Related]
30. Chimeras of labile toxin one and cholera toxin retain mucosal adjuvanticity and direct Th cell subsets via their B subunit.
Boyaka PN; Ohmura M; Fujihashi K; Koga T; Yamamoto M; Kweon MN; Takeda Y; Jackson RJ; Kiyono H; Yuki Y; McGhee JR
J Immunol; 2003 Jan; 170(1):454-62. PubMed ID: 12496431
[TBL] [Abstract][Full Text] [Related]
31. Attenuated Escherichia coli strains expressing the colonization factor antigen I (CFA/I) and a detoxified heat-labile enterotoxin (LThK63) enhance clearance of ETEC from the lungs of mice and protect mice from intestinal ETEC colonization and LT-induced fluid accumulation.
Byrd W; Boedeker EC
Vet Immunol Immunopathol; 2013 Mar; 152(1-2):57-67. PubMed ID: 23122616
[TBL] [Abstract][Full Text] [Related]
32. Combination of Modified NS1 and NS3 as a Novel Vaccine Strategy against Dengue Virus Infection.
Kao YS; Yu CY; Huang HJ; Tien SM; Wang WY; Yang M; Anderson R; Yeh TM; Lin YS; Wan SW
J Immunol; 2019 Oct; 203(7):1909-1917. PubMed ID: 31451673
[TBL] [Abstract][Full Text] [Related]
33. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice.
Amuguni JH; Lee S; Kerstein KO; Brown DW; Belitsky BR; Herrmann JE; Keusch GT; Sonenshein AL; Tzipori S
Vaccine; 2011 Jun; 29(29-30):4778-84. PubMed ID: 21565244
[TBL] [Abstract][Full Text] [Related]
34. Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes.
Gao G; Wang Q; Dai Z; Calcedo R; Sun X; Li G; Wilson JM
Hum Gene Ther; 2008 Sep; 19(9):927-36. PubMed ID: 18788905
[TBL] [Abstract][Full Text] [Related]
35. A vaccine formulation consisting of nucleocapsid-like particles from Dengue-2 and the fusion protein P64k-domain III from Dengue-1 induces a protective immune response against the homologous serotypes in mice.
Lazo L; Gil L; López C; Valdés I; Blanco A; Pavón A; Romero Y; Guzmán MG; Guillén G; Hermida L
Acta Trop; 2012 Nov; 124(2):107-12. PubMed ID: 22750482
[TBL] [Abstract][Full Text] [Related]
36. Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine.
Barrette RW; Szczepanek SM; Rood D; Challa S; Avery N; Vajdy M; Kramer E; Rodriguez L; Silbart LK
Clin Vaccine Immunol; 2011 Nov; 18(11):1996-8. PubMed ID: 21918121
[TBL] [Abstract][Full Text] [Related]
37. DNA vaccines against dengue virus based on the ns1 gene: the influence of different signal sequences on the protein expression and its correlation to the immune response elicited in mice.
Costa SM; Azevedo AS; Paes MV; Sarges FS; Freire MS; Alves AM
Virology; 2007 Feb; 358(2):413-23. PubMed ID: 17020777
[TBL] [Abstract][Full Text] [Related]
38. Development of an anti-dengue NS1 IgG ELISA to evaluate exposure to dengue virus.
Nascimento EJM; George JK; Velasco M; Bonaparte MI; Zheng L; DiazGranados CA; Marques ETA; Huleatt JW
J Virol Methods; 2018 Jul; 257():48-57. PubMed ID: 29567514
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of protective efficacy and immune mechanisms of using a non-structural protein NS1 in DNA vaccine against dengue 2 virus in mice.
Wu SF; Liao CL; Lin YL; Yeh CT; Chen LK; Huang YF; Chou HY; Huang JL; Shaio MF; Sytwu HK
Vaccine; 2003 Sep; 21(25-26):3919-29. PubMed ID: 12922127
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of a recombinant envelope domain III protein of dengue virus type-4 with various adjuvants in mice.
Babu JP; Pattnaik P; Gupta N; Shrivastava A; Khan M; Rao PV
Vaccine; 2008 Aug; 26(36):4655-63. PubMed ID: 18640168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
